A draft report from the Agency for Healthcare Research and Quality examines the research evidence relating to medication therapy management. (AHRQ Report) Medication therapy management, also sometimes referred to as pharmaceutical care, intensively focuses on the drug use of patients and identifies potential issues interfering with maximum value of drug therapies. It results in an individualized care plan for each patient and typically involves ongoing followup. CMS has required Medicare Advantage plans to engage a class of patients with high drug use or expenses in MTM and recently released a proposed rule which would greatly expand the patients for whom the MA plans should be doing MTM. The key questions addressed by the AHRQ report included describing the intervention components and implementation features, assess the effectiveness of MTM on outcomes, identify intervention features or patient characteristics that appear associated with effects on outcomes and identify any potential harms from MTM. Out of a large pool, only 36 studies met the criteria to be included in the review and most of those were considered low strength. Compared to usual care, the outcomes had low strength evidence of improving medication appropriateness, the use of generic medications and lowering the rate of hospitalization among heart failure patients. No benefit was found for most other outcomes examined, including general reduction of hospitalizations or quality of life, but again the evidence for no benefit is low strength. The authors called for a significant improvement in the research to evaluate MTM. The draft report should not be too discouraging to MTM vendors; like most AHRQ systematic reviews the problem is just a lack of good quality studies. The real-life experience of many plans deploying MTM is far more positive than the report would suggest. Properly done research will eventually catch up and validate MTM’s value.
Medication Therapy Management
By Kevin RocheJanuary 15, 2014Commentary
✅ Subscribe via Email
About this Blog
The Healthy Skeptic is a website about the health care system, and is written by Kevin Roche, who has many years of experience working in the health industry. Mr. Roche is available to assist health care companies through consulting arrangements through Roche Consulting, LLC and may be reached at [email protected].
Healthy Skeptic Podcast
This is an outstanding report on total global drug spending and trends, with projections out to 2025. It helps you understand this important area of health care, which does much...
June 1, 2021
MedPAC 2019 Report to Congress
June 18, 2019
CVS has finalized its $10.6 billion buyout of Oak Street health, which operates primary care centers for Medicare members. People may think CVS is a drug store company, but it...
May 4, 2023
Option Care, a large home health care provider is acquiring Amedisys, another large player in that market, for $3.6 billion, as consolidation ramps up across health care, likely meaning higher...
May 4, 2023
Another example of over-priced companies trying to find some way to survive in the post-epidemic financial world. Transcarent, which does something, somehow to “access high quality, affordable care” is buying...
March 6, 2023
Access ACO Care Management Chronic Disease Comparative Effectiveness Consumer Directed Health Consumers Devices Disease Management Drugs EHRs Elder Care End-of-Life Care FDA Financings Genomics Government Health Care Costs Health Care Quality Health Care Reform Health Insurance Health Insurance Exchange HIT HomeCare Hospital Hospital Readmissions Legislation M&A Malpractice Meaningful Use Medicaid Medical Care Medicare Medicare Advantage Mobile Pay For Performance Pharmaceutical Physicians Providers Regulation Repealing Reform Telehealth Telemedicine Wellness and Prevention Workplace
May 30, 2023
The CV-19 and Vax Lies Continue
Three pieces of misleading research or at least reporting of research indicate why science is…
May 29, 2023
Expect More of This
Minnesota's suicide rate has risen by 40% in twenty years. Democrats have been in charge…
May 29, 2023
Some Quick Climate News
CO2 and temperature have a complex relationship and the Arctic isn't going through unprecendented warmth.
Join the discussion One Comment
I suspect that what from a distance appears to be a generic grouping of MTM providers, closer inspection will show a heterogeneity of approaches and efficacies. A quick Medi-span check for drug interactions might qualify as MTM and in which case I am not surprised that the (albeit low strength) evidence showed little benefit. An arrestingly high proportions of hospital readmissions seem to be as a result of ‘medication issues’ so I believe that a detailed MTM review might potentially be a key tool in this regard.